Arsenic trioxide Mylan


arsenic trioxide

This medicine is authorised for use in the European Union.


Arsenic trioxide Mylan is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells) caused by a genetic ‘translocation’ (when there is a swap of genes between two chromosomes). The translocation affects the way the white blood cells grow, and as a result they lack the ability to use retinoic acid (vitamin A). Patients with APL are normally treated with retinoids (substances derived from vitamin A).

Arsenic trioxide Mylan is used in:

  • patients with newly diagnosed low or intermediate risk APL where it is used together with the medicine all-trans-retinoic acid (ATRA);
  • patients with APL whose disease has not responded to previous treatment with a retinoid and cancer medicines, or when their disease has come back after this type of treatment.

Arsenic trioxide Mylan is a ‘generic medicine’. This means that Arsenic trioxide Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Trisenox. For more information on generic medicines, see the question-and-answer document here.

Arsenic trioxide Mylan contains the active substance arsenic trioxide.

This EPAR was last updated on 29/03/2023

Authorisation details

Product details
Arsenic trioxide Mylan
Agency product number
Active substance
Arsenic trioxide
International non-proprietary name (INN) or common name
arsenic trioxide
Therapeutic area (MeSH)
Leukemia, Promyelocytic, Acute
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Mylan Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Unit 35/36
Grange Parade
Industrial Estate
Dublin 13

Product information

24/03/2023 Arsenic trioxide Mylan - EMEA/H/C/005235 - N/0010

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Arsenic trioxide Mylan is indicated for induction of remission, and consolidation in adult patients with:
- Newly diagnosed low to intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/μl) in combination with all trans retinoic acid (ATRA)
- Relapsed/refractory acute promyelocytic leukaemia (APL) (Previous treatment should have included a retinoid and chemotherapy)
characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RAR alpha) gene.

The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been

Assessment history

How useful was this page?

Add your rating